



Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

(Use as many sheets as necessary)

Sheet		of
-------	--	----

Application Number	10/814,701
Filing Date	03/30/2004
First Named Inventor	Blatt; Lawrence M.
Art Unit	1648
Examiner Name	Mosher; Mary
Attorney Docket Number	606319-004502US

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ²
		Country Code* ² Number* ³ Kind Code* ⁴ (if known)				
MM		EP 1213029	06-12-2002	Schering Corp.		
↓		WO 2004/091653	10-28-2004	De Lucia G.		
		WO 2004/108151	12-16-2004	Tan ELC, et al.		
		WO 2004/089983	10-21-2004	Haagmans BL, et al.		

07/09/2007

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (07-05)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Patent and Trademark Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/814,701
Filing Date	03/30/2004
First Named Inventor	Blatt; Lawrence M.
Art Unit	1648
Examiner Name	Mosher; Mary
Attorney Docket Number	606319-004502US

Sheet

of

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MM		Supplementary European Search Report for European patent application Number EP 04749378	
		Annex to the European Search Report on European Patent Application No. EP 04749378	
		Smith AL et al., Antiviral Research, 1987, vol. 8, no. 5/6, pages 239-245.	
		Turner RB et al., 1986, Database Biosis [online] Acc. No.: Prev198682100287, J. Infectious Disease, 154 (3) 443-447	
		Press release by Viragen, June 2, 2003.	
		Feng X, et al., Database WPI, Acc. No. 2004-083733, Derwent Pubs. (GB), CN 1 449 740, October 22, 2003.	
✓		Gao, Z-c, et al., Database Medline, Acc. No. NLM 12837162, Chinese Critical Care Medicine, 15 (6) 332-335, June 2003	

Examiner Signature	/Mary Mosher/	Date Considered	07/09/2007
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

RECEIVED
CENTRAL FAX CENTER

NOV 09 2006

PTO/SB/088 (09-06)

Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/814,701
Filing Date	March 30, 2004
First Named Inventor	Lawrence M. Blatt
Art Unit	1648
Examiner Name	Mary Mosher
Attorney Docket Number	6319-4502US

Sheet 1

of 1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MM		Australian Patent Office Search Report	
		Australian Patent Office Written Opinion	
		Uchiro Fuchizak et al., Synergistic Antiviral Effect of a Combination of Mouse Interferon- α and Interferon- γ on Mouse Hepatitis Virus, J. Med. Virol. 69:188-194 (2003)	
		Jianwu Pei, et al., Chicken Interferon Type I Inhibits Infectious Bronchitis Virus Replication and Associated..., J. Interferon & Cytokine Res. 21:1071-1077 (2001)	
		P.G. Higgins, et al., Intranasal Interferon as Protection Against Experimental Respiratory Coronavirus Infection In Volunteers, Amer. Soc. of Microbiology. pp.713-15 (1983)	

Examiner Signature	/Mary Mosher/	Date Considered	07/09/2007
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-788-9199) and select option 2.



PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 14498/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/814,701		
		Filing Date	March 30, 2004		
		First Named Inventor	Blatt, Lawrence M.		
		Art Unit	1642		
		Examiner Name	To Be Assigned		
Sheet	1	of	1	Attorney Docket Number	INTM-030

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MM		FUCHIZAKI, U. et al. "Synergistic Antiviral Effect of a Combination of Ouse Interferon-alpha and interferon-gama on mouse Hapatitis virus. J. Med. Virol. 2003, Vol. 69, pgs. 188-194	
↓		PEI, J. "Chicken Interferon Type 1 Inhibits Infectious Brochitis Virus Replication and Associated Respiratory Illness. Journal of Interferon and Cytokine Research 2001. Vol. 21, pgs. 1071-107	
↓		HIGGINS, P.G., et al. "Instranasal Interferon as Protection Against Experimental Respiratory Coronavirus Infection in Volunteers", Antimicrobial Agents and Chemotherapy. 1983, Vol. 24, No. 5, pgs. 713-715	

Examiner Signature	/Mary Mosher/	Date Considered	07/09/2007
-----------------------	---------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete If Known	
		Application Number	10/814,701
		Filing Date	March 30, 2004
		First Named Inventor	Blatt, Lawrence M.
		Group Art Unit	1642
Examiner Name	To Be Assigned		
Sheet 2 of 4	Attorney Docket Number	INTM-030	

OTHER ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
MM		Stroher U., et al., J. infect Dis., 2004, Apr1; 189(7)	
		Jones BM, Ma ES et al., Clin Exp Immunol. 2004 Mar; 135(3) 467-73	
		Enserink M., Science. 2004 Feb 27; 303(5662): 1273-5	
		Rimmelzwaan GF, et al., Nat Med. 2004 Mar; 10(3) 290-3	
		Moriguchi H., Sato C., Lancet. 2003 Oct 4; 362(9390): 1159	
		Antonelli G., Lancet. 2003 Oct 4; 362(9390): 1158; author reply 1158-9. No abstract	
		Cinatl J., et al., Lancet 2003 July 26; 362(9390) 293-4	
		Larkin, M., Lancet Infect Dis. 2003 Jul; 3(7) 400	

Examiner Signature	/Mary Mosher/	Date Considered	07/09/2007
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.